Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mediar Therapeutics
Biotech
Eli Lilly to pay Mediar $99M for pulmonary fibrosis prospect
Eli Lilly is making a play for the IPF market, offering Mediar $99 million in upfront and near-term payments for an asset that is entering phase 2.
Nick Paul Taylor
Jan 10, 2025 8:35am
Mediar gets a spark from Pfizer's Ignite program
Oct 25, 2023 10:50am
With $105M and Big Pharma backing, Mediar takes aim at fibrosis
Mar 15, 2023 8:21am
